Loading...

Chembio Diagnostics

Nasdaq:CEMI
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CEMI
Nasdaq
$100M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The last earnings update was 77 days ago. More info.


Add to Portfolio Compare Print
  • Chembio Diagnostics has significant price volatility in the past 3 months.
CEMI Share Price and Events
7 Day Returns
-3.2%
NasdaqCM:CEMI
-0.9%
US Medical Equipment
0.6%
US Market
1 Year Returns
-47.7%
NasdaqCM:CEMI
13.5%
US Medical Equipment
4.1%
US Market
CEMI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Chembio Diagnostics (CEMI) -3.2% 0% -17.7% -47.7% -30.5% 68.1%
US Medical Equipment -0.9% 2.4% 12.5% 13.5% 60.9% 101%
US Market 0.6% 3.8% 2.8% 4.1% 37.3% 42.5%
1 Year Return vs Industry and Market
  • CEMI underperformed the Medical Equipment industry which returned 13.5% over the past year.
  • CEMI underperformed the Market in United States of America which returned 4.1% over the past year.
Price Volatility
CEMI
Industry
5yr Volatility vs Market

CEMI Value

 Is Chembio Diagnostics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Chembio Diagnostics. This is due to cash flow or dividend data being unavailable. The share price is $5.8.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Chembio Diagnostics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Chembio Diagnostics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:CEMI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.65
NasdaqCM:CEMI Share Price ** NasdaqCM (2019-07-17) in USD $5.8
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 41.01x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.98x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Chembio Diagnostics.

NasdaqCM:CEMI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CEMI Share Price ÷ EPS (both in USD)

= 5.8 ÷ -0.65

-8.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Chembio Diagnostics is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Chembio Diagnostics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Chembio Diagnostics's expected growth come at a high price?
Raw Data
NasdaqCM:CEMI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.91x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
80.2%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.3x
United States of America Market PEG Ratio Median Figure of 2,122 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Chembio Diagnostics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Chembio Diagnostics's assets?
Raw Data
NasdaqCM:CEMI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $1.81
NasdaqCM:CEMI Share Price * NasdaqCM (2019-07-17) in USD $5.8
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.32x
United States of America Market PB Ratio Median Figure of 5,241 Publicly-Listed Companies 1.81x
NasdaqCM:CEMI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CEMI Share Price ÷ Book Value per Share (both in USD)

= 5.8 ÷ 1.81

3.21x

* Primary Listing of Chembio Diagnostics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Chembio Diagnostics is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Chembio Diagnostics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Chembio Diagnostics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CEMI Future Performance

 How is Chembio Diagnostics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
80.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Chembio Diagnostics expected to grow at an attractive rate?
  • Chembio Diagnostics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Chembio Diagnostics's earnings growth is expected to exceed the United States of America market average.
  • Chembio Diagnostics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:CEMI Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:CEMI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 80.2%
NasdaqCM:CEMI Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 20.1%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.9%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:CEMI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:CEMI Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 57 0 2
2020-12-31 47 -1 -3 5
2019-12-31 38 -6 -10 5
NasdaqCM:CEMI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 34 -14 -10
2018-12-31 33 -12 -8
2018-09-30 32 -5 -7
2018-06-30 30 -5 -5
2018-03-31 25 -3 -5
2017-12-31 24 -5 -6
2017-09-30 22 -8 -7
2017-06-30 18 -8 -8
2017-03-31 18 -8 -15
2016-12-31 18 -7 -13
2016-09-30 18 -1 -11
2016-06-30 21 0 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Chembio Diagnostics's earnings are expected to grow significantly at over 20% yearly.
  • Chembio Diagnostics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:CEMI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Chembio Diagnostics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CEMI Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.08 0.13 0.02 2.00
2020-12-31 -0.17 -0.08 -0.32 4.00
2019-12-31 -0.58 -0.50 -0.63 4.00
NasdaqCM:CEMI Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.65
2018-12-31 -0.54
2018-09-30 -0.50
2018-06-30 -0.38
2018-03-31 -0.43
2017-12-31 -0.52
2017-09-30 -0.57
2017-06-30 -0.71
2017-03-31 -1.30
2016-12-31 -1.26
2016-09-30 -1.14
2016-06-30 -1.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Chembio Diagnostics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Chembio Diagnostics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Chembio Diagnostics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CEMI Past Performance

  How has Chembio Diagnostics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Chembio Diagnostics's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Chembio Diagnostics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Chembio Diagnostics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Chembio Diagnostics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Chembio Diagnostics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Chembio Diagnostics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CEMI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 33.99 -10.03 12.66
2018-12-31 33.41 -7.87 11.10
2018-09-30 31.80 -6.69 10.32
2018-06-30 30.01 -4.96 9.60
2018-03-31 25.41 -5.41 9.16
2017-12-31 24.02 -6.37 9.11
2017-09-30 22.28 -6.93 9.07 -6.27
2017-06-30 18.44 -8.48 8.60 -4.00
2017-03-31 17.59 -14.66 8.08 -1.63
2016-12-31 17.87 -13.35 7.60
2016-09-30 18.03 -11.44 7.04 7.73
2016-06-30 21.18 -9.74 7.12 7.04
2016-03-31 24.63 -2.05 7.68 6.43
2015-12-31 24.26 -2.40 7.66
2015-09-30 26.93 -2.24 8.24 6.31
2015-06-30 27.36 -2.08 8.26 5.71
2015-03-31 28.06 -1.56 8.05 5.22
2014-12-31 27.65 -1.14 7.53 4.83
2014-09-30 28.41 -0.90 7.10 5.12
2014-06-30 30.71 0.08 6.54 5.75
2014-03-31 28.68 -0.01 5.76 5.99
2013-12-31 29.55 0.53 5.46 5.83
2013-09-30 29.56 1.28 5.03 5.27
2013-06-30 24.95 0.28 4.86 4.67
2013-03-31 25.64 0.82 4.78 4.15
2012-12-31 25.61 0.94 4.85 4.49
2012-09-30 23.96 6.13 4.53 4.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Chembio Diagnostics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Chembio Diagnostics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Chembio Diagnostics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Chembio Diagnostics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Chembio Diagnostics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CEMI Health

 How is Chembio Diagnostics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Chembio Diagnostics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Chembio Diagnostics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Chembio Diagnostics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Chembio Diagnostics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 77.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Chembio Diagnostics Company Filings, last reported 3 months ago.

NasdaqCM:CEMI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 31.06 0.35 7.37
2018-12-31 33.33 0.38 12.52
2018-09-30 19.66 0.41 6.85
2018-06-30 22.01 0.43 9.51
2018-03-31 23.78 0.10 12.46
2017-12-31 13.08 0.10 3.79
2017-09-30 14.94 0.10 1.87
2017-06-30 15.40 0.00 3.69
2017-03-31 17.37 0.00 5.58
2016-12-31 17.17 0.00 10.55
2016-09-30 19.64 0.00 12.17
2016-06-30 9.16 0.00 1.44
2016-03-31 17.41 0.00 2.66
2015-12-31 17.66 0.00 5.38
2015-09-30 18.24 0.00 1.10
2015-06-30 18.61 0.00 1.56
2015-03-31 19.19 0.00 2.82
2014-12-31 19.72 0.00 4.61
2014-09-30 20.11 0.00 3.67
2014-06-30 20.26 0.00 6.84
2014-03-31 20.18 0.00 9.09
2013-12-31 20.18 0.00 9.65
2013-09-30 20.39 0.00 8.05
2013-06-30 19.61 0.00 8.65
2013-03-31 14.26 0.00 2.60
2012-12-31 13.87 0.13 2.95
2012-09-30 13.28 0.15 3.29
  • Chembio Diagnostics's level of debt (1.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 1.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Chembio Diagnostics has less than a year of cash runway based on current free cash flow.
  • Chembio Diagnostics has less than a year of cash runway if free cash flow continues to grow at historical rates of 54.9% each year.
X
Financial health checks
We assess Chembio Diagnostics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Chembio Diagnostics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CEMI Dividends

 What is Chembio Diagnostics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Chembio Diagnostics dividends.
If you bought $2,000 of Chembio Diagnostics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Chembio Diagnostics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Chembio Diagnostics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:CEMI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:CEMI Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Chembio Diagnostics has not reported any payouts.
  • Unable to verify if Chembio Diagnostics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Chembio Diagnostics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Chembio Diagnostics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Chembio Diagnostics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Chembio Diagnostics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Chembio Diagnostics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CEMI Management

 What is the CEO of Chembio Diagnostics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Sperzel
COMPENSATION $1,456,097
AGE 55
TENURE AS CEO 5.3 years
CEO Bio

Mr. John J. Sperzel, III, B.Sc., has been the Chief Executive Officer and President of Chembio Diagnostics, Inc. since March 13, 2014. Mr. Sperzel is on leave of Absence on May 30, 2017. Mr. Sperzel served as the Chief Executive Officer of International Technidyne Corporation since September 2011 until December 2013. He serves as an Advisor to the board of the Diagnostic Marketing Association. Mr. Sperzel served as President of Axis-Shield Inc. at Axis-Shield PLC since August 11, 2004. He served as Vice President of World Wide Marketing and Business Development for Near Patient Testing at Bayer Diagnostics. He has worked in the Diagnostics Industry for 25 years at Roche (Boehringer Mannheim), Instrumentation Laboratory and Bayer HealthCare. He joined Axis-Shield in 2004 from Bayer Diagnostics, where he served as Vice President of Worldwide Marketing and Business Development for Near Patient Testing. He was the president of the board of Diagnostic Marketing Association since 2007. He served as a Director of International Technidyne Corporation since September 2011 until December 2013. He has been a Director of diaDexus Inc since June 2015. He has been a Director of Chembio Diagnostics, Inc. since March 2014. Mr. Sperzel holds a B.S. in Business Administration/Management Degree from Plymouth State College (Plymouth NH).

CEO Compensation
  • John's compensation has increased whilst company is loss making.
  • John's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Chembio Diagnostics management team in years:

2.6
Average Tenure
55
Average Age
  • The tenure for the Chembio Diagnostics management team is about average.
Management Team

John Sperzel

TITLE
President
COMPENSATION
$1M
AGE
55
TENURE
5.3 yrs

Neil Goldman

TITLE
Executive VP & CFO
COMPENSATION
$647K
AGE
51
TENURE
1.6 yrs

Javan Esfandiari

TITLE
Chief Science & Technology Officer and Executive VP
COMPENSATION
$813K
AGE
52
TENURE
15.5 yrs

David Gyorke

TITLE
Senior VP & COO
AGE
59
TENURE
2.5 yrs

Christine Rousseau

TITLE
Vice President of Corporate Development
TENURE
1 yrs

Robert Passas

TITLE
Senior VP & Chief Commercial Officer
COMPENSATION
$271K
AGE
65
TENURE
2.8 yrs

Konstantin Lyashchenko

TITLE
Research Director of Chembio Diagnostic Systems Inc
COMPENSATION
$106K
Board of Directors Tenure

Average tenure and age of the Chembio Diagnostics board of directors in years:

2
Average Tenure
63
Average Age
  • The average tenure for the Chembio Diagnostics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Kathy Davis

TITLE
Chair of the Board
COMPENSATION
$75K
AGE
63
TENURE
5.3 yrs

John Sperzel

TITLE
President
COMPENSATION
$1M
AGE
55
TENURE
5.3 yrs

Gail Page

TITLE
Independent Director
COMPENSATION
$25K
AGE
64
TENURE
2 yrs

John Potthoff

TITLE
Independent Director
COMPENSATION
$168K
AGE
51
TENURE
1.2 yrs

Mary Polan

TITLE
Independent Director
COMPENSATION
$208K
AGE
75
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • Chembio Diagnostics individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
24. May 19 Sell Javan Esfandiari Individual 22. May 19 24. May 19 -30,000 $7.41 $-214,434
16. Nov 18 Buy John Potthoff Individual 14. Nov 18 14. Nov 18 20,000 $5.81 $116,150
06. Nov 18 Buy Robert Passas Individual 05. Nov 18 05. Nov 18 15,000 $6.75 $101,250
X
Management checks
We assess Chembio Diagnostics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Chembio Diagnostics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CEMI News

Simply Wall St News

Chembio Diagnostics (NASDAQ:CEMI) Shareholders Booked A 69% Gain In The Last Five Years

For the last half decade, Chembio Diagnostics can boast revenue growth at a rate of 0.7% per year. … The modest growth is probably broadly reflected in the share price, which is up 11%, per year over 5 years. … This free report showing analyst forecasts should help you form a view on Chembio Diagnostics A Different Perspective Chembio Diagnostics shareholders are down 48% for the year, but the market itself is up 7.2%.

Simply Wall St -

What Kind Of Share Price Volatility Should You Expect For Chembio Diagnostics, Inc. (NASDAQ:CEMI)?

Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … This is above 1, so historically its share price has been influenced by the broader volatility of the stock market. … What this means for you: Since Chembio Diagnostics has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment.

Simply Wall St -

Does Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) CEO Salary Compare Well With Others?

We took a group of companies with market capitalizations below US$200m, and calculated the median CEO total compensation to be US$451k. … Thus we can conclude that John Sperzel receives more in total compensation than the median of a group of companies in the same market, and of similar size to Chembio Diagnostics, Inc.. … We compared the total CEO remuneration paid by Chembio Diagnostics, Inc., and compared it to remuneration at a group of similar sized companies.

Simply Wall St -

Have Insiders Been Buying Chembio Diagnostics, Inc. (NASDAQ:CEMI) Shares This Year?

We often see insiders buying up shares in companies that perform well over the long term. … So shareholders might well want to know whether insiders have been buying or selling shares in Chembio Diagnostics, Inc. … The Last 12 Months Of Insider Transactions At Chembio Diagnostics.

Simply Wall St -

Do Insiders Own Lots Of Shares In Chembio Diagnostics, Inc. (NASDAQ:CEMI)?

A look at the shareholders of Chembio Diagnostics, Inc. … With a market capitalization of US$101m, Chembio Diagnostics is a small cap stock, so it might not be well known by many institutional investors. … Check out our latest analysis for Chembio Diagnostics

Simply Wall St -

Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) CEO Pay Fair?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does John Sperzel's Compensation Compare With Similar Sized Companies. … has a market cap of US$119m, and is paying total annual CEO compensation of US$542k.

Simply Wall St -

Does Chembio Diagnostics, Inc. (NASDAQ:CEMI) Have A Particularly Volatile Share Price?

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Dilution Ahead For Chembio Diagnostics, Inc. (NASDAQ:CEMI) Shareholders?

The single most important question to ask when you’re investing in a loss-making company is – will they need to raise cash again, and if so, when? … Today I’ve examined Chembio Diagnostics’s financial data from its most recent earnings update, to roughly assess when the company may need to raise new capital. … Chembio Diagnostics currently has US$6.8m in the bank, with negative cash flows from operations of -US$5.4m

Simply Wall St -

Have Insiders Been Buying Chembio Diagnostics, Inc. (NASDAQ:CEMI) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Chembio Diagnostics, Inc. … In any event it's generally a positive if insiders are buying shares at around the current price. … In total, Chembio Diagnostics insiders bought more than they sold over the last year

Simply Wall St -

Do Directors Own Chembio Diagnostics Inc (NASDAQ:CEMI) Shares?

The big shareholder groups in Chembio Diagnostics Inc (NASDAQ:CEMI) have power over the company. … Generally speaking, as a company grows, institutions will increase their ownership. … Chembio Diagnostics is not a large company by global standards.

Simply Wall St -

CEMI Company Info

Description

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and LumiraDx to develop POC diagnostic tests for infectious diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Details
Name: Chembio Diagnostics, Inc.
CEMI
Exchange: NasdaqCM
Founded: 1985
$99,565,462
17,166,459
Website: http://chembio.com
Address: Chembio Diagnostics, Inc.
3661 Horseblock Road,
Medford,
New York, 11763,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CEMI Common Stock Nasdaq Capital Market US USD 18. Oct 2000
BST D9IA Common Stock Boerse-Stuttgart DE EUR 18. Oct 2000
Number of employees
Current staff
Staff numbers
295
Chembio Diagnostics employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/18 00:02
End of day share price update: 2019/07/17 00:00
Last estimates confirmation: 2019/06/17
Last earnings filing: 2019/05/02
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.